"In general, I think there's a tremendous amount of variability in terms of how sexual medicine specialists treat patients who have had intimacy issues relating to robotic prostatectomy," says Stanton Honig, MD.
In this video, experts from Yale University in New Haven, Connecticut highlight the background and findings from the study, “How do Sexual Medicine Specialists Handle Patient Counseling and Penile Rehabilitation in Patients Undergoing Robotic Assisted Radical Prostatectomy (ralp): Trends in Pre Op and Post Operative Management,” which was presented at the 24th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America in San Diego, California.
Video Transcript:
Dylan Heckscher, MD: Prostatectomy is one of the most common surgeries performed in the United States, and the vast majority of patients who undergo prostatectomy do not return to their baseline functioning in terms of erectile function. There were some guidelines published back in 2021, outlining the lack of high quality evidence for perioperative care for restoring erectile function post surgically. So, we polled a variety of different sexual medicine specialists here at SMSNA last year, and found that essentially, there's a large variability in preoperative counseling, post operative management, and not all of it is in accordance with the guidelines, and neither is our own practice. We think it highlights the need for future research specifically on this subject to get higher quality evidence.
Stanton Honig, MD: In general, I think there's a tremendous amount of variability in terms of how sexual medicine specialists treat patients who have had intimacy issues relating to robotic prostatectomy. Some people treat preoperatively, some people treat only postoperatively, some people see patients preoperatively, some people only see patients postoperatively. So, we're interested in looking at patient satisfaction with respect to what works best in terms of counseling them on the options for intimacy after a prostate cancer treatment.
Katherine L. Rotker, MD: On that same front, I think that beyond just the medical treatments and surgical treatments we can offer these patients after the prostate cancer treatment, building the relationship, counseling appropriately, giving realistic expectations, and a plan is hugely valuable beyond the guidelines and the limited data we have for the efficacy of the treatments themselves.
This transcription has been edited for clarity.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.